Teleflex Incorporated $TFX Stock Holdings Reduced by Invenomic Capital Management LP

Invenomic Capital Management LP lowered its position in Teleflex Incorporated (NYSE:TFX) by 10.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 346,559 shares of the medical technology company’s stock after selling 39,113 shares during the quarter. Teleflex makes up approximately 2.0% of Invenomic Capital Management LP’s holdings, making the stock its 10th biggest position. Invenomic Capital Management LP’s holdings in Teleflex were worth $42,294,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Banque Cantonale Vaudoise grew its stake in Teleflex by 82.5% in the fourth quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock valued at $31,000 after purchasing an additional 113 shares in the last quarter. Hantz Financial Services Inc. grew its stake in Teleflex by 40.5% in the fourth quarter. Hantz Financial Services Inc. now owns 392 shares of the medical technology company’s stock valued at $48,000 after purchasing an additional 113 shares in the last quarter. UMB Bank n.a. grew its stake in Teleflex by 57.1% in the fourth quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock valued at $38,000 after purchasing an additional 113 shares in the last quarter. Maryland State Retirement & Pension System grew its stake in Teleflex by 1.5% in the fourth quarter. Maryland State Retirement & Pension System now owns 8,652 shares of the medical technology company’s stock valued at $1,056,000 after purchasing an additional 129 shares in the last quarter. Finally, CIBC Asset Management Inc grew its stake in Teleflex by 3.4% in the fourth quarter. CIBC Asset Management Inc now owns 4,380 shares of the medical technology company’s stock valued at $535,000 after purchasing an additional 145 shares in the last quarter. Hedge funds and other institutional investors own 95.62% of the company’s stock.

Teleflex Stock Performance

TFX opened at $125.08 on Thursday. The company has a market cap of $5.54 billion, a PE ratio of -5.49, a price-to-earnings-growth ratio of 0.95 and a beta of 0.82. The stock has a 50-day moving average of $129.31 and a 200-day moving average of $119.24. Teleflex Incorporated has a 52-week low of $100.18 and a 52-week high of $139.67. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.03 and a current ratio of 2.55.

Teleflex (NYSE:TFX) last released its quarterly earnings results on Thursday, May 7th. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.21 by $0.18. The company had revenue of $548.30 million during the quarter, compared to the consensus estimate of $536.91 million. Teleflex had a positive return on equity of 13.29% and a negative net margin of 35.88%.The firm’s revenue was up 32.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.44 EPS. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. As a group, equities research analysts forecast that Teleflex Incorporated will post 6.7 earnings per share for the current fiscal year.

Teleflex Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Monday, May 25th will be paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 1.1%. The ex-dividend date is Friday, May 22nd. Teleflex’s dividend payout ratio is -5.96%.

Analyst Upgrades and Downgrades

A number of research analysts have commented on TFX shares. Piper Sandler upgraded Teleflex from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $140.00 to $160.00 in a research note on Monday, June 8th. Wall Street Zen downgraded Teleflex from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Weiss Ratings restated a “sell (d)” rating on shares of Teleflex in a research note on Friday, March 27th. Truist Financial restated a “hold” rating and issued a $143.00 target price (up from $135.00) on shares of Teleflex in a research note on Monday, May 11th. Finally, Zacks Research upgraded Teleflex from a “strong sell” rating to a “hold” rating in a research note on Tuesday, April 28th. Four equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $146.00.

Teleflex Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.